Presented at ASCO GU 2025, results of the phase 3 TALAPRO-2 trial support a new standard-of-care for metastatic castration-resistant prostate cancer
Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…
Results of the multi-center, international phase 3 TALAPRO-2 trial show that the combination of PARP inhibitor talazoparib plus anti-androgen enzalutamide…
The second Joint Action of the EU on Networks of Expertise on Cancer (JANE-2) officially launched on January 28-29, 2025,…
The Paseíco de la Mama solidarity initiative has enabled VHIO’s Breast Cancer Group to carry out numerous research projects over…
Published in the journal Nature Communications*, results from a first-in-human, phase I clinical trial of an oral, potent and reversible…
Dr. Raquel Pérez-Lopez, head of the Radiomics Group at VHIO and coordinator of the Oncology Commission of the Spanish Society…
Published in Cell Reports Medicine*, results of a VHIO-led study support the feasibility of using RAD51 testing to complement next-generation…
Presented today at the ASCO Gastrointestinal Cancers Symposium, 23-25 January in San Francisco, results of 2 phase 3 clinical studies…
The European Commission has approved dostarlimab in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary…
Breathing is life, but for millions of people living with lung diseases, each breath can be a constant struggle. These…
This is the third clinical trial carried out with OMO-103, a drug developed at the Vall d’Hebron Institute of Oncology…
Published in Clinical Cancer Research*, a journal of the American Association for Cancer Research (AACR), results of a VHIO-led study…
Led by Thierry Andre, Head of the Department of Medical Oncology at the Hôpital Saint Antoine in Paris, the phase…
